News & Blogs

WSJ Editorial Board: A Toxic Drug-Price Deal

So much for self-reflection after a political drubbing. Democrats are responding to last week’s defeat by rushing President Biden’s spending framework through the House while rewriting it on the fly—and they’ll worry about the consequences later. Consider the latest compromise to reduce drug prices, which will do the opposite. Progressives hope that passing legislation in the name of lower prices will increase senior support for their spending bill. But some House Democrats balked at earlier…

Learn More

Dan Leonard: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars

Americans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs. But the wholesale policy changes now under rushed consideration in Congress will undermine the only proven solution to this long-standing problem: competition from Food and Drug Administration-approved generic and biosimilar medicines. Generic and biosimilar medicines generated $2 trillion in savings to the U.S. health care system over the last decade. Yet proposals in the reconciliation package will jeopardize the development of these less-expensive drugs, harming…

Learn More

Sally Pipes: Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Just a few days ago, it appeared that Democrats had given up on including prescription drug pricing reforms in their massive spending bill. But not anymore. In an eleventh-hour turn of events, congressional Democrats this week resurrected their long-standing desire to levy government price controls on prescription drugs. If lawmakers successfully deploy their latest price-control gambit, then patients today and in the future will miss out on state-of-the-art treatments that will never be invented. According to early reports,…

Learn More

Kent Kaiser: Congress: Drive a Stake Through the Heart of Socialist Drug Price Controls

The Lower Drug Costs Now Act (H.R. 3) and similar proposals keep rearing their heads in Congress with the purported aim of lowering prescription drug prices and improving Medicare. The problem is, such proposals are shortsighted and ultimately lead to lower quality, fewer options, and diminished health outcomes. H.R. 3, which has been around for years and like a vampire just won’t seem to die, would cap prescription drug prices at no more than 120 percent of…

Learn More

Jon Decker: The AARP wants price controls, but do they have the interests of seniors at heart?

As evidenced by AARP State Director Sam Wilson’s recent Kenosha News op-ed, AARP Wisconsin has been pushing hard for a bevy of new, federal healthcare regulations. These changes, supported by House Speaker Nancy Pelosi, would fundamentally reshape America’s Medicare system, imposing draconian, nationwide price controls over the cost of prescription drugs. Why, then, is the AARP supportive of such a radical policy? For that answer, simply follow the money. It may surprise many to learn…

Learn More

Erik Paulsen: Why Democrats Must Drop Drug Price Controls

The future of the Democrats’ $3.5 trillion spending bill could come down to an intra-party showdown on a single issue: drug pricing. On September 15, the House Energy & Commerce Committee, deferring to moderate Democrats, rejected a plan to let the government interfere in the price of drugs purchased through Medicare. Later that day, in an exercise of progressive political muscle, the House Ways and Means Committee approved a nearly identical measure.Some on the progressive…

Learn More

Chris Jacobs: How AARP Puts Profits over Patients—And Principles

Why would an organization that claims to represent seniors support legislation that discriminates against the most vulnerable and raids Medicare to pay for unrelated left-wing spending priorities? When it comes to AARP, it’s all about the money—its own money. As a report I recently wrote for American Commitment demonstrates, AARP has become an organization that compromises its own purported principles to take advantage of its members for its own bottom line. The tax-exempt AARP doesn’t get most…

Learn More

Grace-Marie Turner: Democrats’ Drug Price Controls Threaten Biotech Research, Patients

There are too many dreadful provisions in Democrats’ $3.5 trillion spending monstrosity to count, but one is rising to the surface as especially destructive. That would be its prescription drug price-control schemes. A study by University of Chicago economist Tomas Philipson and analyst Troy Durie concludes that the Congressional Budget Office is wrong by more than an order of magnitude in its estimates of how many new and better drugs would be lost if this legislation were to be enacted.…

Learn More